ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the National Comprehensive ...
ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) ...
ImmunityBio (IBRX) stock jumps as NCCN guidelines recommend an additional use for the company's bladder cancer therapy, Anktiva. Read more here.
ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...
Endometriosis is a complex disease that affects the reproductive system and can lower the chance of pregnancy. Medical ...
The company now expects a longer path to approval than anticipated, leading it to deprioritize a therapy billed as a threat ...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate ...
Medindia on MSN
Blood in Urine? Why Early Scans Detect Bladder Cancer Faster
India, March 17 -- Latest study shows a serious link between emergency room wait times and patient survival. One in ten ...
Stocktwits on MSN
Why did IBRX stock jump 7% in pre-market today?
Shares of ImmunityBio Inc. (IBRX) climbed more than 7% in pre-market trading on Tuesday, after a key update to its U.S. cancer treatment guidelines expanded the recommended use of its lead therapy ...
If you get a high reading at the doctor's office, it may not be definitive. Here's what to know about your risk — and testing ...
We are curing more cancers than we used to,” Cottrill said. “Recurrent cancers are more challenging to cure than cancers that ...
In this episode of From Bench to Bedside and Beyond, Dr. Yaw Nyame and patient Dave Lucas discuss the robotic surgical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results